The U.S. Food and Drug Administration on November 10, 2026, ordered manufacturers of all GLP-1 medications to add new warning labels tied to a rare condition that can permanently destroy vision.
The condition, nonarteritic anterior ischemic optic neuropathy, known as NAION, can strike suddenly and leave patients blind, The Guardian reported. GLP-1 drugs are widely used to facilitate weight loss.
Among the medications now required to carry the NAION warning are Ozempic and Wegovy, both made by Novo Nordisk, and Mounjaro and Zepbound, both from Eli Lilly. Sanofi's Soliqua is also covered by the mandate, The Guardian said.
NBC News and The Guardian both reported the FDA's announcement on November 10, 2026.